Relay Therapeutics, Inc. (RLAY)

Market Cap	773.96M
Revenue (ttm)	25.55M
Net Income (ttm)	-341.97M
Shares Out	131.18M
EPS (ttm)	-2.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	782,653
Open	5.97
Previous Close	5.95
Day's Range	5.86 - 6.01
52-Week Range	5.78 - 13.32
Beta	1.63
Analysts	Strong Buy
Price Target	23.30 (+294.92%)
Earnings Date	May 2, 2024

About RLAY

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibit...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 16, 2020
• Employees: 323
• Stock Exchange: NASDAQ
• Ticker Symbol: RLAY

Financial Performance

In 2023, RLAY's revenue was $25.55 million, an increase of 1749.82% compared to the previous year's $1.38 million. Losses were -$341.97 million, 17.7% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for RLAY stock is "Strong Buy." The 12-month stock price forecast is $23.3, which is an increase of 294.92% from the latest price.

Price Target

$23.3

(294.92% upside)

Analyst Consensus: Strong Buy